Sector Gamma AS Buys 25,301 Shares of Lantheus Holdings, Inc. $LNTH

Sector Gamma AS boosted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 101.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,301 shares of the medical equipment provider's stock after purchasing an additional 25,301 shares during the quarter. Lantheus comprises approximately 1.3% of Sector Gamma AS's investment portfolio, making the stock its 29th biggest position. Sector Gamma AS owned about 0.07% of Lantheus worth $4,118,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Liberty One Investment Management LLC boosted its position in shares of Lantheus by 6.9% in the second quarter. Liberty One Investment Management LLC now owns 10,634 shares of the medical equipment provider's stock valued at $870,000 after acquiring an additional 687 shares during the period. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Lantheus in the second quarter valued at about $246,000. DekaBank Deutsche Girozentrale boosted its position in shares of Lantheus by 7.6% in the second quarter. DekaBank Deutsche Girozentrale now owns 10,551 shares of the medical equipment provider's stock valued at $866,000 after acquiring an additional 746 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Lantheus in the second quarter valued at about $1,812,000. Finally, William Blair Investment Management LLC boosted its position in shares of Lantheus by 7.7% in the second quarter. William Blair Investment Management LLC now owns 391,622 shares of the medical equipment provider's stock valued at $32,058,000 after acquiring an additional 27,855 shares during the period. Institutional investors own 99.06% of the company's stock.

Insider Activity

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,812,000 shares of company stock valued at $382,427,380. Insiders own 1.50% of the company's stock.

Lantheus Stock Down 1.1%

Shares of NASDAQ LNTH opened at $56.51 on Friday. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. The company has a market cap of $3.84 billion, a price-to-earnings ratio of 15.03 and a beta of 0.09. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $118.21. The stock has a 50-day moving average price of $54.10 and a two-hundred day moving average price of $72.24.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The firm had revenue of $92.51 million during the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. As a group, analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of recent research reports. William Blair reissued a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. JMP Securities cut their price objective on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research report on Thursday, August 7th. Mizuho cut their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. Truist Financial set a $63.00 price objective on shares of Lantheus and gave the stock a "hold" rating in a research report on Monday, August 11th. Finally, TD Cowen cut their price objective on shares of Lantheus from $95.00 to $80.00 and set a "buy" rating for the company in a research report on Monday, September 15th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Lantheus currently has a consensus rating of "Moderate Buy" and a consensus target price of $74.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.